Lactulose+ linaclotide

Phase 3Peptide

Lactulose+ linaclotide is one of 4 small molecule programs targeting Bowel Preparation for Colonoscopy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bowel Preparation for ColonoscopyEnrolling by invitation

Bowel Preparation for ColonoscopyPhase 3

Enrolling by invitation

Competition

Competitive Landscape

3 competitors in Bowel Preparation for Colonoscopy

#DrugCompanyPhaseTrials

Golytely

Bayer

Approved

2 2

Chronulac

SSolvay Pharmaceuticals

Approved

2 3

Lactulose+ linaclotide

HHaifeng Lan

Phase 3

1 4

Golytely

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bowel Preparation for Colonoscopy1 trial

Clinical Study on the Application of Lactulose Combined with Linaclotide in Bowel Preparation for Colonoscopy

Enrolling by invitation·HHaifeng Lan·Phase 4·NCT06748638·444 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lactulose+ linaclotide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lactulose+ linaclotide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lactulose+ linaclotide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Haifeng Lan company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 3[1]
Company: HHaifeng Lan

Lactulose+ linaclotide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bowel Preparation for Colonoscopy1 trial

References

Drug Info

Quick Facts

Related News